A randomized, double-blind, placebo-controlled trial of TAK-242 for the treatment of severe sepsis
TW Rice, AP Wheeler, GR Bernard… - Critical care …, 2010 - journals.lww.com
Objective: To evaluate whether TAK-242, a small-molecule inhibitor of Toll-like receptor-4–
mediated signaling, suppresses cytokine levels and improves 28-day all-cause mortality
rates in patients with severe sepsis. Design: Randomized, double-blind, placebo-controlled
trial. Setting: A total of 93 intensive care units worldwide. Patients: A total of 274 patients with
severe sepsis and shock or respiratory failure. Interventions: Patients were randomly
assigned to receive a 30-min loading dose followed by 96-hr infusions of placebo, TAK-242 …
mediated signaling, suppresses cytokine levels and improves 28-day all-cause mortality
rates in patients with severe sepsis. Design: Randomized, double-blind, placebo-controlled
trial. Setting: A total of 93 intensive care units worldwide. Patients: A total of 274 patients with
severe sepsis and shock or respiratory failure. Interventions: Patients were randomly
assigned to receive a 30-min loading dose followed by 96-hr infusions of placebo, TAK-242 …